MRNA vs GILD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
GILD Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Gilead Sciences Inc (GILD) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus GILD at 16.4x Forward P/E and 38.2% operating margin (+6.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against GILD sits in SURGE (61st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | GILD Revenue | MRNA Op. Margin | GILD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $22.1B | -306.0% | 37.1% | GILD |
| FY2019 | $60M | $22.4B | -906.8% | 19.1% | GILD |
| FY2020 | $800M | $24.7B | -95.0% | 16.5% | GILD |
| FY2021 | $18.5B | $27.3B | 72.0% | 36.3% | MRNA |
| FY2022 | $19.3B | $27.3B | 48.9% | 26.9% | MRNA |
| FY2023 | $6.85B | $27.1B | -61.9% | 28.0% | GILD |
| FY2024 | $3.24B | $28.8B | -121.9% | 5.8% | GILD |
| FY2025 | $1.94B | $29.4B | -158.1% | 34.0% | GILD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | GILD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $206.6B | Larger Scale | GILD |
| Trailing P/E Ratio Valuation | 23.0x | 16.8x | Lower Multiple | GILD |
| Forward P/E Ratio Valuation | 23.0x | 16.4x | Lower Multiple | GILD |
| Revenue Growth (YoY) Growth | +29.2% | +6.8% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 38.2% | Higher Margin | GILD |
| Net Profit Margin Profitability | -110.5% | -12.5% | Higher Margin | GILD |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -22.4% | Higher ROE | GILD |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 83% ($117โ$177) | Stronger Trend | GILD |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.31ฮฒ ยท 30% Vol | Lower Realized Risk | GILD |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 42.9 / 100 (HOLD) | Higher Composite | GILD |